AbbVie Completes Acquisition of Apogee Therapeutics

AbbVie’s acquisition (via Apogee) deepens its immunology pipeline by adding diverse late-stage assets targeting dermatologic, respiratory, and other inflammatory diseases. The lead candidate, zumilokibart, is a half-life extended monoclonal antibody targeting IL-13 and is described as late-stage in development, supporting continued expansion of AbbVie’s immunology growth platform.